Recursion Pharmaceuticals call volume above normal and directionally bullish
Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 5,540 calls trading, 2x expected, and implied vol increasing over 2 points to 75.26%. Jan-27 5 calls and Nov-24 8 calls are the most active options, with total volume in those strikes near 3,500 contracts. The Put/Call Ratio is 0.10. Earnings are expected on November 7th.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXRX:
- Recursion Pharmaceuticals doses first patient in Phase 2 trial of REC-3964
- Cathie Wood’s ARK Investment buys 425K shares of Recursion Pharmaceuticals today
- Cathie Wood’s ARK Investment buys 124K shares of Recursion Pharmaceuticals today
- Recursion Pharmaceuticals’ Groundbreaking Cancer Drug Enters Clinical Trials
- Recursion receives FDA clearance for Phase 1/2 clinical trial of REC-1245
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.